Caffine and Endurance PerformancePACENCT05404841
Investigating the Effect of Whole-fruit Coffee Extract on Exercise Performance
A study testing CoffeeBerry Supplement in people with Caffine and Endurance Performance, run by University of Exeter at 2 sites in United Kingdom.
Trial summary
Caffeine is a widely used efficacious supplement by both the general public, and athletes, with the goal of improving performance. The effects of caffeine alone are well known, but it is not clear whether a multi-ingredient supplement (containing both caffeine and polyphenols) can affect exercise performance. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Caffine and Endurance Performance
- What is being tested?
- CoffeeBerry Supplement
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 14 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- 4 Feb 2022to 25 Jan 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age 18-40
- Heathy
- Highly trained endurance athletes (V̇O2max: males >55 and females >50 mL⋅kg bm-1⋅min-1)
- Both males and females are allowed to participate. If females are on the oral contraceptive pill they are to be tested on consecutive weeks. If they are not on the oral contraceptive pill, then female subjects are to be tested every 4 weeks, at the same point of their menstrual cycle.
Who cannot join
- Allergy to Lidocaine
- Any diagnosed metabolic health condition
- Pregnant
- Non-habitual caffeine intake
- Smoker
- No endurance training
Show all 9Show fewer
- Diagnosed Cardiovascular disease
- Beta-Blockers
- Recent history of musculoskeletal injury
Trial locations and contacts
2 sites in 1 country.
United Kingdom2 sites
Sport & Health Sciences University of Exeter
Exeter, Devon, EX1 2LU
University of Exeter
Exeter, EX1 2LU
About this study
Caffeine is a widely used efficacious supplement by both the general public, and athletes, with the goal of improving performance. The effects of caffeine alone are well known, but it is not clear whether a multi-ingredient supplement (containing both caffeine and polyphenols) can affect exercise performance.
This study aims to determine if a low dose of caffeine, in the form of a whole-fruit coffee extract also containing polyphenols, can improve exercise performance compared to a placebo condition, with a secondary objective of identifying if this supplement can improve post exercise refuelling (glycogen resynthesis).
Read more
Participants will consume either the supplement or a placebo before engaging in an exercise protocol. Muscle biopsies will then be obtained so as to measure subsequent glycogen resynthesis, with multiple blood samples being taken through the day. The following morning another biopsy will be taken before the exercise protocol will be repeated.
This research will inform us of the efficacy of caffeine and polyphenols on improving exercise performance.
- Conditions
- Caffine and Endurance Performance
- Being tested
- CoffeeBerry Supplement, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CoffeeBerry SupplementDietary supplement
A Coffeeberry supplement containing 200mg Caffeine and 14mg polyphenols, manufactured by FutureCeuticals Inc.,
PlaceboDietary supplement
Placebo
| Study group | Role | What they receive |
|---|---|---|
| CoffeeBerry Supplement | Experimental | Caffeine and polyphenol supplement Receives: Dietary Supplement: CoffeeBerry Supplement |
| Placebo | Placebo comparator | Placebo Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Exercise performance
Amount of work completed in 15 minutes
Measured: 15 Minitues
Secondary outcomes (6)
Glycogen Resynthesis
The diffrence in glycogen within the muscle between two time points
Measured: 24 Hours
Alertness
10 cm visual analog scale (Ranging from Not Alert to Extremly Alert)
Measured: 1 Minitue
Motivation
10 cm visual analog scale (Ranging from Not motivated to Extremly motivated)
Measured: 1 Minitue
Rate of perceived exertion
Validated Borg scale (6-20 Arbitrary units)
Measured: 1 Minitue
Urine osmolarity
The hydration status of the individual measured in mOsmo|/kg
Measured: 24 Hours
GI comfort
10 cm visual analog scale (Ranging from No discomfort to Extreme discomfort)
Measured: 1 Minitue
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jun 2022
- Study start4 Feb 2022
- Primary completion25 Jan 2023
- Study completion25 Jan 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Caffine and Endurance PerformanceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 14 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Exeter
- Sponsor type
- University, hospital or other
- Collaborators
- VDF FutureCeuticals Inc.
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05404841
- Sponsor's protocol ID
- 2021-10-20-B-05
- Acronym
- PACE
- Status last verified
- Mar 2023
- First submitted
- 10 Jan 2022
- Last updated
- 22 Mar 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Pavis GF, Kingma RL, Nemzer BV, Abshiru N, Wall BT, Stephens FB. An extract from whole Coffea arabica coffee cherry improves time trial performance, but not muscle glycogen resynthesis, in trained cyclists. J Int Soc Sports Nutr. 2026 Dec 31;23(1):2682323. doi: 10.1080/15502783.2026.2682323. Epub 2026 Jun 3.
PubMed 42234539
Study at a glance
From the registry record, last updated by the sponsor on 22 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigating the Effect of Whole-fruit Coffee Extract on Exercise Performance
- ClinicalTrials.gov ID
- NCT05404841
- Acronym / sponsor ID
- PACE / 2021-10-20-B-05
- Conditions
- Caffine and Endurance Performance
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 14 participants (actual)
- Lead sponsor
- University of ExeterUniversity, hospital or other
- Collaborators
- VDF FutureCeuticals Inc.
- Study start
- 4 Feb 2022 (actual)
- Primary completion
- 25 Jan 2023 (actual)
- Study completion
- 25 Jan 2023 (actual)
- First posted
- 3 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Caffeine is a widely used efficacious supplement by both the general public, and athletes, with the goal of improving performance. The effects of caffeine alone are well known, but it is not clear whether a multi-ingredient supplement (containing both caffeine and polyphenols) can affect exercise performance.
This study aims to determine if a low dose of caffeine, in the form of a whole-fruit coffee extract also containing polyphenols, can improve exercise performance compared to a placebo condition, with a secondary objective of identifying if this supplement can improve post exercise refuelling (glycogen resynthesis).
Participants will consume either the supplement or a placebo before engaging in an exercise protocol. Muscle biopsies will then be obtained so as to measure subsequent glycogen resynthesis, with multiple blood samples being taken through the day. The following morning another biopsy will be taken before the exercise protocol will be repeated.
This research will inform us of the efficacy of caffeine and polyphenols on improving exercise performance.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CoffeeBerry Supplement | Experimental | Dietary Supplement: CoffeeBerry SupplementCaffeine and polyphenol supplement |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboPlacebo |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Age 18-40
- Heathy
- Highly trained endurance athletes (V̇O2max: males >55 and females >50 mL⋅kg bm-1⋅min-1)
- Both males and females are allowed to participate. If females are on the oral contraceptive pill they are to be tested on consecutive weeks. If they are not on the oral contraceptive pill, then female subjects are to be tested every 4 weeks, at the same point of their menstrual cycle.
Key exclusion criteria (9 listed)
- Allergy to Lidocaine
- Any diagnosed metabolic health condition
- Pregnant
- Non-habitual caffeine intake
- Smoker
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CoffeeBerry SupplementA Coffeeberry supplement containing 200mg Caffeine and 14mg polyphenols, manufactured by FutureCeuticals Inc., | Dietary supplement | CoffeeBerry Supplement |
| PlaceboPlacebo | Dietary supplement | Placebo |
Primary outcome
Exercise performance
Time frame: 15 Minitues
Amount of work completed in 15 minutes
6 secondary outcomes
Glycogen Resynthesis
Time frame: 24 Hours
Alertness
Time frame: 1 Minitue
Motivation
Time frame: 1 Minitue
Rate of perceived exertion
Time frame: 1 Minitue
Urine osmolarity
Time frame: 24 Hours
GI comfort
Time frame: 1 Minitue
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Mar 2023.
- Derived from this study: PubMed 42234539Pavis GF, Kingma RL, Nemzer BV, Abshiru N, Wall BT, Stephens FB. An extract from whole Coffea arabica coffee cherry improves time trial performance, but not muscle glycogen resynthesis, in trained cyclists. J Int Soc Sports Nutr. 2026 Dec 31;23(1):2682323. doi: 10.1080/15502783.2026.2682323. Epub 2026 Jun 3.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CoffeeBerry Supplement in people with Caffine and Endurance Performance, run by University of Exeter at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Exercise performance (time frame: 15 Minitues). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05404841, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Mar 2023.